NASDAQ:TLSI TriSalus Life Sciences (TLSI) Stock Price, News & Analysis $4.74 +0.22 (+4.87%) (As of 12:20 PM ET) Add Compare Share Share Today's Range$4.64▼$4.7950-Day Range$4.52▼$5.8952-Week Range$3.32▼$10.42Volume36,317 shsAverage Volume39,507 shsMarket Capitalization$128.73 millionP/E RatioN/ADividend YieldN/APrice Target$13.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get TriSalus Life Sciences alerts: Email Address TriSalus Life Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside166.0% Upside$12.50 Price TargetShort InterestHealthy0.64% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.14Based on 14 Articles This WeekInsider TradingAcquiring Shares$63,954 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.52 out of 5 starsMedical Sector92nd out of 927 stocksSurgical & Medical Instruments Industry15th out of 101 stocks 3.5 Analyst's Opinion Consensus RatingTriSalus Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTriSalus Life Sciences has only been the subject of 2 research reports in the past 90 days.Read more about TriSalus Life Sciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.64% of the float of TriSalus Life Sciences has been sold short.Short Interest Ratio / Days to CoverTriSalus Life Sciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TriSalus Life Sciences has recently decreased by 19.95%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTriSalus Life Sciences does not currently pay a dividend.Dividend GrowthTriSalus Life Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TLSI. Previous Next 3.4 News and Social Media Coverage News SentimentTriSalus Life Sciences has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for TriSalus Life Sciences this week, compared to 1 article on an average week.MarketBeat Follows3 people have added TriSalus Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TriSalus Life Sciences insiders have bought 127,808.00% more of their company's stock than they have sold. Specifically, they have bought $63,954.00 in company stock and sold $50.00 in company stock.Percentage Held by Insiders76.20% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.58% of the stock of TriSalus Life Sciences is held by institutions.Read more about TriSalus Life Sciences' insider trading history. Previous Next N/A Earnings and Valuation Read more about TriSalus Life Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About TriSalus Life Sciences Stock (NASDAQ:TLSI)TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.Read More TLSI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TLSI Stock News HeadlinesSeptember 14 at 9:11 AM | insidertrades.comInsider Buying: TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Acquires 7,520 Shares of StockSeptember 13 at 8:44 AM | insidertrades.comMary T. Szela Buys 5,000 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) StockSeptember 16, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…September 16 at 7:11 AM | americanbankingnews.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Acquires $39,104.00 in StockSeptember 16 at 5:43 AM | americanbankingnews.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Down 20.0% in AugustSeptember 14 at 5:45 AM | finance.yahoo.comTriSalus Life Sciences Inc (TLSI) CEO Buys SharesAugust 21, 2024 | uk.finance.yahoo.comTriSalus Life Sciences, Inc. (TLSIW)August 18, 2024 | investing.comTriSalus stock holds Buy rating with $11 targetSeptember 16, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…August 16, 2024 | msn.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | finanznachrichten.deTriSalus Reports Q2 2024 Financial Results and Business UpdateAugust 15, 2024 | msn.comTLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q2 2024August 1, 2024 | stockhouse.comTriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference CallJune 26, 2024 | businesswire.comTriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to WarrantsJune 3, 2024 | businesswire.comTriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual MeetingMay 24, 2024 | businesswire.comTriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to WarrantsMay 16, 2024 | seekingalpha.comTLSI TriSalus Life Sciences, Inc.May 16, 2024 | msn.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q1 2024 Earnings Call TranscriptSee More Headlines Receive TLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/16/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:TLSI Previous SymbolNASDAQ:TLSI CUSIPN/A CIK1826667 Webtrisaluslifesci.com Phone888-321-5212FaxN/AEmployees106Year FoundedN/APrice Target and Rating Average Stock Price Target$12.50 High Stock Price Target$16.00 Low Stock Price Target$10.00 Potential Upside/Downside+180.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,040,000.00 Net Margins-219.71% Pretax Margin-219.67% Return on EquityN/A Return on Assets-192.99% Debt Debt-to-Equity RatioN/A Current Ratio2.33 Quick Ratio2.04 Sales & Book Value Annual Sales$24.74 million Price / Sales5.22 Cash FlowN/A Price / Cash FlowN/A Book Value($0.98) per share Price / Book-4.85Miscellaneous Outstanding Shares27,159,000Free Float6,464,000Market Cap$129.01 million OptionableNot Optionable Beta0.48 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMs. Mary T. Szela B.S.N. (Age 60)M.B.A., CEO, President & Director Comp: $880.67kMr. Sean Edward Murphy (Age 71)CFO & Director Comp: $628.75kDr. Steven C. Katz F.A.C.S. (Age 49)M.D., Chief Medical Officer & Chairman of Scientific Advisory Board Comp: $849.89kMs. Lori Ann SantamariaVice President of OperationsDr. Bryan F. Cox Ph.D. (Age 62)Chief Scientific & Manufacturing Officer Mr. James E. YoungSenior VP of Investor Relations & TreasurerMs. Rachel GarciaMarketing ManagerDr. Richard B. Marshak M.B.A. (Age 65)MBA, VMD, Senior Vice President of Corporate Development & Strategy Ms. Jennifer L. Stevens J.D. (Age 63)Chief Regulatory Officer Comp: $630kMs. Jodi Devlin (Age 62)President of Commercial Operations More ExecutivesKey CompetitorsAxoGenNASDAQ:AXGNZimVieNASDAQ:ZIMVJin Medical InternationalNASDAQ:ZJYLButterfly NetworkNYSE:BFLYNano-X ImagingNASDAQ:NNOXView All CompetitorsInsiders & InstitutionsMary T SzelaBought 7,520 shares on 9/12/2024Total: $39,104.00 ($5.20/share)Mary T SzelaBought 5,000 shares on 9/10/2024Total: $24,850.00 ($4.97/share)George Kelly MartinSold 9 sharesTotal: $49.50 ($5.50/share)Duquesne Family Office LLCBought 110,966 shares on 8/15/2024Ownership: 1.572%Highbridge Capital Management LLCBought 214,545 shares on 8/12/2024Ownership: 0.790%View All Insider TransactionsView All Institutional Transactions TLSI Stock Analysis - Frequently Asked Questions How have TLSI shares performed this year? TriSalus Life Sciences' stock was trading at $8.45 at the beginning of the year. Since then, TLSI shares have decreased by 44.4% and is now trading at $4.70. View the best growth stocks for 2024 here. How were TriSalus Life Sciences' earnings last quarter? TriSalus Life Sciences, Inc. (NASDAQ:TLSI) issued its earnings results on Wednesday, August, 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. The business earned $7.36 million during the quarter. Who are TriSalus Life Sciences' major shareholders? Top institutional investors of TriSalus Life Sciences include Duquesne Family Office LLC (1.57%), Highbridge Capital Management LLC (0.79%) and Wolverine Asset Management LLC (0.16%). Insiders that own company stock include Mary T Szela and George Kelly Martin. View institutional ownership trends. How do I buy shares of TriSalus Life Sciences? Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TLSI) was last updated on 9/16/2024 by MarketBeat.com Staff From Our Partners44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TriSalus Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
